Adjunct Immunotherapies for Tuberculosis

Adjunct immunotherapies for tuberculosis.

The continued spread of multidrug-resistant (MDR) tuberculosis and extensively drug-resistant tuberculosis poses a major threat to global tuberculosis control. Treatment is complex and requires longer use of more-expensive, less effective, and toxic anti-tuberculosis drugs, which results in high morbidity and mortality. The poor treatment outcomes and the slow progress in the development and ev...

Immunotherapies for Type 1 Diabetes

Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF.

Studies in mouse infection models clearly demonstrate tumour necrosis factor (TNF) to be a critical component of both the antibacterially protective and the inflammatory immune response to Mycobacterium tuberculosis. It is therefore not surprising that treatment of patients-for example, those with rheumatoid arthritis-with biological agents interfering with TNF activity have shown an increased ...

Immunotherapies: cause for measured optimism.

exciting potential that the field of immunotherapeutics offers for human health and economic reward was show-cased at the first European Therapeutic Vaccine Congress (27–28 June 2002; London, UK). Data from 19 ongoing or recently completed Phase I–III clinical trials were presented by 11 biotechnology companies and one academic group. Conspicuous by their absence were clinical presentations fro...

Suppress for Success: A JAK Inhibitor for Adjunct Therapy of Tuberculosis

Standard chemotherapy of tuberculosis (TB), which is caused by infection withMycobacterium tuberculosis (Mtb) and which primarily affects the lung, consists of a combination of antimicrobial drugs (isoniazid, rifampin, ethambutol and pyrazinamide). Concomitant administration of these antimicrobials helps eradicate active infection and prevents disease relapse (Zumla et al., 2015). In most patie...